2018 Global Animal Antimicrobials and Antibiotics Market Forecasts By Products, Animals & Mode Of Delivery

DALLAS July 3, 2014

Antimicrobials and antibiotics form a major share of the animal health market. Animal antimicrobials gained a greater importance in the animal health industry in the past 20 years, mainly due to growing need to preserve the health and welfare of animals. Most of the antimicrobial agents were also used as growth promoters as well. With this, the animal antimicrobials market witnessed a bullish growth from 1990's to 2006.

However, gradually, there were growing concerns about emergence of antibiotic-resistant bacteria which led to worldwide initiatives to minimize the use of antimicrobial agents as a growth promoter in food-producing animals. In Europe, in 2006, a complete ban was imposed on use of antimicrobial agents in food-producing animals, which brought a huge setback to the growing market for antimicrobial and antibiotics in Europe.

At present, the global antimicrobials and antibiotics market is driven by the growing need to preserve animal health owing to rising demand for animal proteins across the globe, and growing demand in the companion animals segment. Growing livestock population, increasing incidences of disease outbreaks and increase in the companion animal ownership are some of the factors driving the growth of this market to a certain extent. Besides the structural market drivers, there are strong geographic drivers for the growth of the animal antimicrobials and antibiotics market. The emerging markets are becoming increasingly attractive. The Asian and Latin American region form one of the most promising animal antimicrobials and antibiotics markets in the world. Developing countries such as China and India have a relatively high CAGR rate and are expected to witness significant market growth in the forecast period. The growth in these regions is mainly attributed to the rise in demand for animal protein products, along with an increase in the trend of companion animal ownership in these regions.

Today, the animal antimicrobials and antibiotics market showcase a sluggish growth, owing to the regulatory authorities restricting their use, increased usage of in-feed enzymes, competitive exclusion products and probiotics as an alternative to antibiotics and prophylactic use of antibiotics being replaced by good husbandry, environment and hygienic practices.

Tetracyclines dominated the animal antimicrobials and antibiotics product segment in 2013, accounting for around 60% of the market revenue. This was followed by others segment, which accounted for 16% of the global animal antimicrobials and antibiotics product market in 2013. In the global antimicrobials and antibiotics animal market, pigs dominated the market with a share of close to 25%. In the mode of delivery segment of animal antimicrobials and antibiotics market, premix was the major revenue contributor in 2013, with an estimated share of nearly 49%.

North America dominated the animal antimicrobials and antibiotics market in 2013. However, the market share of this region will decrease to 27%, primarily due to the regulatory ban on the use of antibiotics announced in the U.S. At the same time, Asia and Latin America are poised to grow at a CAGR of 6% to 8% in the forecast period; this growth is largely driven by the increased urbanization, rising disposable incomes, increase in the demand for animal products and the increasing trend of pet ownerships in these regions.

The global animal antimicrobials and antibiotics market is consolidated with Zoetis Inc. (U.S.), Elanco Animal Health (U.S.), Merck Animal Health (U.S.), Merial (U.S.), Bayer Animal Health (Germany) holding around 75% of the total market. Other major players in this market are Virbac Animal Health (U.S.), and CEVA Santé Animale (U.S.).

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…